AI Generated Image
Eli Lilly to offer retatrutide access given earlier to just one patient
STAT • • business
Key Points:
- Eli Lilly has confirmed it will allow more patients to apply for early access to retatrutide, an unapproved obesity drug, following initial reports of a single patient receiving special access.
- This decision follows inquiries from STAT about expanded access requests from doctors that had not yet been addressed by the company.
- Lilly stated that early access will be granted to a limited number of patients who meet specific medical criteria and cannot enroll in clinical trials, aligning with FDA guidance.
- The pharmaceutical company is actively reviewing requests from healthcare providers for this special access program.
- This marks a notable shift in Lilly's previously limited communication regarding retatrutide's special access availability.
